In early studies, sera from pregnant women, as well as those from patients with Sjögren syndrome or systemic lupus erythematosus (SLE), exhibited increased antibody reactivity against a peptide corresponding to a predicted epitope from the ERV3–1 envelope glycoprotein and to recombinant protein (105). Here, ERV3-1 is linked to systemic lupus erythematosus.